Spontaneous iliopsoas hematoma in a patient with moderate hemophilia B
DOI:
https://doi.org/10.32818/reccmi.a10n3a17Keywords:
hemophilia B, hematoma, psoas musclesAbstract
Iliopsoas hematomas are a serious complication of hemophilia B. In this case, a patient with moderate hemophilia B and a factor IX activity level of 1.7% also had a spontaneous iliopsoas hematoma. Diagnosis was made using computed tomography (CT), and treatment consisted primarily of factor IX replacement at 40 IU/kg every 12 hours, reaching a target factor IX level of 65% by day 8 of the treatment regimen. This case highlights the importance of suspecting iliopsoas hematomas in patients with hemophilia who present with abdominopelvic pain. It is important to order CT or MRI scans and measure factor IX activity levels to confirm the suspicion and initiate factor IX replacement early. Furthermore, consultation with a surgical or interventional radiology service is recommended if the hematoma is refractory to medical treatment or if the patient presents with femoral neuropathy or compartment syndrome.
Downloads
Metrics
References
Howdary P, Carcao M, Kenet G, Pipe SW. Haemophilia. Lancet. 2025; 405(10480): 736-50. doi: https://doi.org/10.1016/S0140-6736(24)02139-1 (último acceso dic. 2025). DOI: https://doi.org/10.1016/S0140-6736(24)02139-1
Sidonio RF Jr, Malec L. Hemophilia B (Factor IX Deficiency). Hematol Oncol Clin North Am. 2021; 35(6): 1143-55. doi: https://doi.org/10.1016/j.hoc.2021.07.008 (último acceso dic. 2025). DOI: https://doi.org/10.1016/j.hoc.2021.07.008
Rezende SM, Neumann I, Angchaisuksiri P, Awodu O, Boban A, Cuker A, et al. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the GRADE methodology. J Thromb Haemost. 2024; 22(9): 2629-52. doi: https://doi.org/10.1016/j.jtha.2024.05.026 (último acceso dic. 2025). DOI: https://doi.org/10.1016/j.jtha.2024.05.026
Rodriguez-Merchan EC. Complications of muscle hematomas in hemophilia. Cardiovasc Hematol Disord Drug Targets. 2020; 20(4): 242-48. doi: https://doi.org/10.2174/1871529X20666200415121409 (último acceso dic. 2025). DOI: https://doi.org/10.2174/22124063MTA13ODMnz
Rodriguez-Merchan EC, De la Corte-Rodriguez H. Iliopsoas hematomas in people with hemophilia: diagnosis and treatment. Expert Rev Hematol. 2020; 13(8): 781-89. doi: https://doi.org/10.1080/17474086.2020.1787146 (último acceso dic. 2025). DOI: https://doi.org/10.1080/17474086.2020.1787146
Garge S, Mahajan A, Atluri S, Baliyan V, Singh A, Jain S, et al. Role of endovascular embolization in treatment of acute bleeding complications in haemophilia patients. Br J Radiol. 2016; 89(1060): 20151064. doi: https://doi.org/10.1259/bjr.20151064 (último acceso dic. 2025). DOI: https://doi.org/10.1259/bjr.20151064
Wojciechowski J, Gaitonde P, Hughes JH, Ravva P. Population modeling of factor IX activity following administration of fidanacogene elaparvovec gene therapy in participants with hemophilia B. Clin Pharmacokinet. 2025; 64(10): 1531-48. doi: https://doi.org/10.1007/s40262-025-01443-0 (último acceso dic. 2025). DOI: https://doi.org/10.1007/s40262-025-01535-y
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ana Xcaret Tisnado-Quevedo, Antonio Osuna-López, Rigoberto Castillo-Leva, Daniela Páez-Lizárraga
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
